Gujarat Themis Biosyn Ltd

💰 Gujarat Themis Biosyn Acquires Sanofi Portfolio with €62M Revenue in FY2025

- Acquired Sanofi's global anti-TB and anti-infective portfolio for €158 million.

- Portfolio includes 13 established brands present in over 55 countries.

- Generated €62 million in revenue in FY2025.

- Structured as an asset-light model—brands, marketing authorizations, dossiers, and inventory included.

- Portfolio features WHO Essential Medicines and EU Critical Drugs, with ~70% revenue from retail channels.

- Strategic benefits: access to regulated/semi-regulated markets and forward integration potential from API to finished dosage.

- Transition to a high-margin fermentation-based platform aimed at improving operational efficiency.

- Post-acquisition focus: market expansion, lifecycle management, reactivation of dormant authorizations, and portfolio optimization.